283 related articles for article (PubMed ID: 33769276)
41. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.
Liu W; Morito D; Takashima S; Mineharu Y; Kobayashi H; Hitomi T; Hashikata H; Matsuura N; Yamazaki S; Toyoda A; Kikuta K; Takagi Y; Harada KH; Fujiyama A; Herzig R; Krischek B; Zou L; Kim JE; Kitakaze M; Miyamoto S; Nagata K; Hashimoto N; Koizumi A
PLoS One; 2011; 6(7):e22542. PubMed ID: 21799892
[TBL] [Abstract][Full Text] [Related]
42. Disease Variant Landscape of a Large Multiethnic Population of Moyamoya Patients by Exome Sequencing.
Shoemaker LD; Clark MJ; Patwardhan A; Chandratillake G; Garcia S; Chen R; Morgan AA; Leng N; Kirk S; Chen R; Cook DJ; Snyder M; Steinberg GK
G3 (Bethesda); 2015 Nov; 6(1):41-9. PubMed ID: 26530418
[TBL] [Abstract][Full Text] [Related]
43. Clinical characteristics and intracranial arterial lesions of non-young adult ischemic stroke patients with RNF213 p.R4810K variant.
Ogura S; Ohara T; Tanaka E; Ashida S; Maezono-Kandori K; Hanya M; Mizuta I; Mizuno T
J Neurol Sci; 2023 Sep; 452():120775. PubMed ID: 37657303
[TBL] [Abstract][Full Text] [Related]
44. Significant Association of the RNF213 p.R4810K Polymorphism with Quasi-Moyamoya Disease.
Morimoto T; Mineharu Y; Kobayashi H; Harada KH; Funaki T; Takagi Y; Sakai N; Miyamoto S; Koizumi A
J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2632-2636. PubMed ID: 27476341
[TBL] [Abstract][Full Text] [Related]
45. Biochemical and Functional Characterization of RNF213 (Mysterin) R4810K, a Susceptibility Mutation of Moyamoya Disease, in Angiogenesis In Vitro and In Vivo.
Kobayashi H; Matsuda Y; Hitomi T; Okuda H; Shioi H; Matsuda T; Imai H; Sone M; Taura D; Harada KH; Habu T; Takagi Y; Miyamoto S; Koizumi A
J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26126547
[TBL] [Abstract][Full Text] [Related]
46. Significant association of RNF213 p.R4810K, a moyamoya susceptibility variant, with coronary artery disease.
Morimoto T; Mineharu Y; Ono K; Nakatochi M; Ichihara S; Kabata R; Takagi Y; Cao Y; Zhao L; Kobayashi H; Harada KH; Takenaka K; Funaki T; Yokota M; Matsubara T; Yamamoto K; Izawa H; Kimura T; Miyamoto S; Koizumi A
PLoS One; 2017; 12(4):e0175649. PubMed ID: 28414759
[TBL] [Abstract][Full Text] [Related]
47. Early onset of moyamoya syndrome in a Down syndrome patient with the genetic variant RNF213 p.R4810K.
Chong PF; Ogata R; Kobayashi H; Koizumi A; Kira R
Brain Dev; 2015 Sep; 37(8):822-4. PubMed ID: 25547042
[TBL] [Abstract][Full Text] [Related]
48. Association of
Xue Y; Zeng C; Ge P; Liu C; Li J; Zhang Y; Zhang D; Zhang Q; Zhao J
Stroke; 2022 Sep; 53(9):2906-2916. PubMed ID: 35543128
[TBL] [Abstract][Full Text] [Related]
49. Pediatric renovascular hypertension: Treatment outcome according to underlying disease.
Lee Y; Lim YS; Lee ST; Cho H
Pediatr Int; 2018 Mar; 60(3):264-269. PubMed ID: 29281158
[TBL] [Abstract][Full Text] [Related]
50. Differing phenotypes of Moyamoya disease in a familial case involving heterozygous c.14429G > A variant in RNF213.
Inoue T; Murakami N; Sakadume S; Kido Y; Kikuchi A; Ichinoi N; Suzuki K; Kure S; Sakuta R
Pediatr Int; 2015 Aug; 57(4):798-801. PubMed ID: 26315205
[TBL] [Abstract][Full Text] [Related]
51. Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G>A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients.
Hitomi T; Habu T; Kobayashi H; Okuda H; Harada KH; Osafune K; Taura D; Sone M; Asaka I; Ameku T; Watanabe A; Kasahara T; Sudo T; Shiota F; Hashikata H; Takagi Y; Morito D; Miyamoto S; Nakao K; Koizumi A
Biochem Biophys Res Commun; 2013 Aug; 438(1):13-9. PubMed ID: 23850618
[TBL] [Abstract][Full Text] [Related]
52. Prospective Screening of Extracranial Systemic Arteriopathy in Young Adults with Moyamoya Disease.
Jee TK; Yeon JY; Kim SM; Bang OY; Kim JS; Hong SC
J Am Heart Assoc; 2020 Oct; 9(19):e016670. PubMed ID: 32954918
[TBL] [Abstract][Full Text] [Related]
53. A case of hemichorea in RNF213-related vasculopathy.
Hosoki S; Yoshimoto T; Ihara M
BMC Neurol; 2021 Jan; 21(1):32. PubMed ID: 33482763
[TBL] [Abstract][Full Text] [Related]
54. The Clinical and Vascular Characteristics of RNF213 c.14576G>A Variant-Related Intracranial Major Artery Disease in China.
Cheng W; Xue S; Wu F; Song X; Huang Q; Song H; Wu J
Behav Neurol; 2019; 2019():7908392. PubMed ID: 30992731
[TBL] [Abstract][Full Text] [Related]
55. A Polymorphism in RNF213 Is a Susceptibility Gene for Intracranial Atherosclerosis.
Bang OY; Chung JW; Cha J; Lee MJ; Yeon JY; Ki CS; Jeon P; Kim JS; Hong SC
PLoS One; 2016; 11(6):e0156607. PubMed ID: 27253870
[TBL] [Abstract][Full Text] [Related]
56. Genetic variant RNF213 c.14576G>A in various phenotypes of intracranial major artery stenosis/occlusion.
Miyawaki S; Imai H; Shimizu M; Yagi S; Ono H; Mukasa A; Nakatomi H; Shimizu T; Saito N
Stroke; 2013 Oct; 44(10):2894-7. PubMed ID: 23970789
[TBL] [Abstract][Full Text] [Related]
57. Frequency of the moyamoya-related RNF213 p.Arg4810Lys variant in 1,516 Korean individuals.
Jang MA; Shin S; Yoon JH; Ki CS
BMC Med Genet; 2015 Nov; 16():109. PubMed ID: 26590131
[TBL] [Abstract][Full Text] [Related]
58. Can Moyamoya Disease Susceptibility Gene Affect Extracranial Systemic Artery Stenosis?
Nomura S; Aihara Y; Akagawa H; Chiba K; Yamaguchi K; Kawashima A; Okada Y; Kawamata T
J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104532. PubMed ID: 31806452
[TBL] [Abstract][Full Text] [Related]
59. [Precision Medicine for Moyamoya Disease].
Fujimura M
No Shinkei Geka; 2022 Jan; 50(1):216-221. PubMed ID: 35169101
[TBL] [Abstract][Full Text] [Related]
60. De Novo Development of Moyamoya Disease after Stereotactic Radiosurgery for Brain Arteriovenous Malformation in a Patient With RNF213 p.Arg4810Lys (rs112735431).
Torazawa S; Miyawaki S; Shinya Y; Kawashima M; Hasegawa H; Dofuku S; Uchikawa H; Kin T; Shin M; Nakatomi H; Saito N
World Neurosurg; 2020 Aug; 140():276-282. PubMed ID: 32434013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
